1. Hum Mol Genet. 2014 Sep 1;23(17):4479-90. doi: 10.1093/hmg/ddu160. Epub 2014
Apr  8.

Comprehensive functional annotation of 18 missense mutations found in suspected 
hemochromatosis type 4 patients.

Callebaut I(1), Joubrel R(2), Pissard S(3), Kannengiesser C(4), Gérolami V(5), 
Ged C(6), Cadet E(7), Cartault F(8), Ka C(2), Gourlaouen I(2), Gourhant L(9), 
Oudin C(4), Goossens M(3), Grandchamp B(4), De Verneuil H(6), Rochette J(7), 
Férec C(2), Le Gac G(10).

Author information:
(1)IMPMC, Sorbonne Universités - UMR CNRS 7590, UPMC Univ Paris 06, Muséum 
d'Histoire Naturelle, IRD UMR 206, Paris, France.
(2)Laboratoire de Génétique Moléculaire et d'Histocompatibilité, Inserm U1078, 
Université de Brest, SFR SnInBioS, CHRU de Brest, Etablissement Français du Sang 
- Bretagne, Brest, France.
(3)Laboratoire de Génétique, UPEC (Université Paris Est Creteil), GHU Henri 
Mondor, Créteil, France.
(4)Hôpital Bichat, Département de Génétique, Inserm U1149 - Center for Research 
on Inflammation, Université Paris Diderot, AP-HP, Paris, France.
(5)Biologie Moléculaire, CHU de Marseille, Hôpital Conception.
(6)Inserm U1035, Biothérapies des Maladies Génétiques et Cancers, Université de 
Bordeaux, CHU de Bordeaux, Pôle de Biologie et Pathologie, Bordeaux, France.
(7)Laboratoire de Génétique Moléculaire, UPJV EA4666, CHU d'Amiens, Amiens, 
France.
(8)Service de Génétique, CHU de la Réunion, Saint-Denis, France and.
(9)CHRU de Brest, Inserm CIC0502, Brest, France.
(10)Laboratoire de Génétique Moléculaire et d'Histocompatibilité, Inserm U1078, 
Université de Brest, SFR SnInBioS, CHRU de Brest, Etablissement Français du Sang 
- Bretagne, Brest, France CHRU de Brest, Inserm CIC0502, Brest, France 
gerald.legac@univ-brest.fr.

Hemochromatosis type 4 is a rare form of primary iron overload transmitted as an 
autosomal dominant trait caused by mutations in the gene encoding the iron 
transport protein ferroportin 1 (SLC40A1). SLC40A1 mutations fall into two 
functional categories (loss- versus gain-of-function) underlying two distinct 
clinical entities (hemochromatosis type 4A versus type 4B). However, the vast 
majority of SLC40A1 mutations are rare missense variations, with only a few 
showing strong evidence of causality. The present study reports the results of 
an integrated approach collecting genetic and phenotypic data from 44 suspected 
hemochromatosis type 4 patients, with comprehensive structural and functional 
annotations. Causality was demonstrated for 10 missense variants, showing a 
clear dichotomy between the two hemochromatosis type 4 subtypes. Two subgroups 
of loss-of-function mutations were distinguished: one impairing cell-surface 
expression and one altering only iron egress. Additionally, a new 
gain-of-function mutation was identified, and the degradation of ferroportin on 
hepcidin binding was shown to probably depend on the integrity of a large 
extracellular loop outside of the hepcidin-binding domain. Eight further 
missense variations, on the other hand, were shown to have no discernible 
effects at either protein or RNA level; these were found in apparently isolated 
patients and were associated with a less severe phenotype. The present findings 
illustrate the importance of combining in silico and biochemical approaches to 
fully distinguish pathogenic SLC40A1 mutations from benign variants. This has 
profound implications for patient management.

© The Author 2014. Published by Oxford University Press. All rights reserved. 
For Permissions, please email: journals.permissions@oup.com.

DOI: 10.1093/hmg/ddu160
PMID: 24714983 [Indexed for MEDLINE]